135 related articles for article (PubMed ID: 20486280)
1. Are coronary revascularization and myocardial infarction a homogeneous combined endpoint in hypertension trials? The Losartan Intervention For Endpoint reduction in hypertension study.
Cicala S; de Simone G; Gerdts E; Dahlöf B; Lindholm LH; Kjeldsen SE; Devereux RB
J Hypertens; 2010 Jun; 28(6):1134-40. PubMed ID: 20486280
[TBL] [Abstract][Full Text] [Related]
2. Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention for Endpoint reduction in hypertension study.
Kjeldsen SE; Devereux RB; Hille DA; Lyle PA; Dahlöf B; Julius S; Edelman JM; Snapinn SM; de Faire U; Fyhrquist F; Ibsen H; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Blood Press; 2009; 18(6):348-61. PubMed ID: 20001655
[TBL] [Abstract][Full Text] [Related]
3. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
4. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
5. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).
Smebye ML; Iversen EK; Høieggen A; Flaa A; Os I; Kjeldsen SE; Olsen MH; Chattopadhyay A; Hille DA; Lyle PA; Devereux RB; Dahlöf B
Am J Cardiol; 2007 Sep; 100(5):855-9. PubMed ID: 17719333
[TBL] [Abstract][Full Text] [Related]
6. Serial evaluation of electrocardiographic left ventricular hypertrophy for prediction of risk in hypertensive patients.
Okin PM
J Electrocardiol; 2009; 42(6):584-8. PubMed ID: 19631946
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Lehto M; Gerdts E; Olsen MH; Hornestam B; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):712-9. PubMed ID: 15734615
[TBL] [Abstract][Full Text] [Related]
8. Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
Li Z; Dahlöf B; Okin PM; Kjeldsen SE; Wachtell K; Ibsen H; Nieminen MS; Jern S; Devereux RB
J Hypertens; 2008 Jun; 26(6):1244-9. PubMed ID: 18475164
[TBL] [Abstract][Full Text] [Related]
9. Potential mechanisms of stroke benefit favoring losartan in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Devereux RB; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):443-57. PubMed ID: 17288698
[TBL] [Abstract][Full Text] [Related]
10. The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
Fossum E; Moan A; Kjeldsen SE; Devereux RB; Julius S; Snapinn SM; Edelman JM; de Faire U; Fyhrquist F; Ibsen H; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Dahlöf B;
J Am Coll Cardiol; 2005 Sep; 46(5):770-5. PubMed ID: 16139123
[TBL] [Abstract][Full Text] [Related]
11. Impact of lower achieved blood pressure on outcomes in hypertensive patients.
Okin PM; Hille DA; Kjeldsen SE; Dahlöf B; Devereux RB
J Hypertens; 2012 Apr; 30(4):802-10; discussion 810. PubMed ID: 22343536
[TBL] [Abstract][Full Text] [Related]
12. Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the LIFE study.
Nordestgaard BG; Kontula K; Benn M; Dahlöf B; de Faire U; Edelman JM; Eliasson E; Fyhrquist F; Hille DA; Ibsen H; Lyle PA; Berg K; Sandberg M; Sethi AA; Wong PH; Os I
Pharmacogenet Genomics; 2010 Feb; 20(2):77-85. PubMed ID: 20065889
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
Wachtell K; Hornestam B; Lehto M; Slotwiner DJ; Gerdts E; Olsen MH; Aurup P; Dahlöf B; Ibsen H; Julius S; Kjeldsen SE; Lindholm LH; Nieminen MS; Rokkedal J; Devereux RB
J Am Coll Cardiol; 2005 Mar; 45(5):705-11. PubMed ID: 15734614
[TBL] [Abstract][Full Text] [Related]
14. Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.
Olsen MH; Wachtell K; Beevers G; Dahlöf B; de Simone G; Devereux RB; de Faire U; Fyhrquist F; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Lyle PA; Nieminen MS; Omvik P; Oparil S; Wedel H
J Hypertens; 2009 Mar; 27(3):567-74. PubMed ID: 19262226
[TBL] [Abstract][Full Text] [Related]
15. Reductions in albuminuria and in electrocardiographic left ventricular hypertrophy independently improve prognosis in hypertension: the LIFE study.
Olsen MH; Wachtell K; Ibsen H; Lindholm LH; Dahlöf B; Devereux RB; Kjeldsen SE; Oikarinen L; Okin PM;
J Hypertens; 2006 Apr; 24(4):775-81. PubMed ID: 16531808
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
17. Lack of regression of left ventricular hypertrophy is associated with higher incidence of revascularization in hypertension: The LIFE Study.
Søraas CL; Wachtell K; Okin PM; Dahlöf B; Devereux RB; Tønnessen T; Kjeldsen SE; Olsen MH
Blood Press; 2010 Jun; 19(3):145-51. PubMed ID: 20429689
[TBL] [Abstract][Full Text] [Related]
18. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.
Dahlöf B; Devereux R; de Faire U; Fyhrquist F; Hedner T; Ibsen H; Julius S; Kjeldsen S; Kristianson K; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H
Am J Hypertens; 1997 Jul; 10(7 Pt 1):705-13. PubMed ID: 9234823
[TBL] [Abstract][Full Text] [Related]
19. Changes in electrocardiographic left ventricular hypertrophy and risk of major cardiovascular events in isolated systolic hypertension: the LIFE study.
Larstorp AC; Okin PM; Devereux RB; Olsen MH; Ibsen H; Dahlöf B; Kjeldsen SE; Wachtell K
J Hum Hypertens; 2011 Mar; 25(3):178-85. PubMed ID: 20505749
[TBL] [Abstract][Full Text] [Related]
20. Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Olsen MH; Wachtell K; Bella JN; Palmieri V; Gerdts E; Smith G; Nieminen MS; Dahlöf B; Ibsen H; Devereux RB
Am J Hypertens; 2005 Nov; 18(11):1430-6. PubMed ID: 16280277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
